

Vimpat[®] (lacosamide) – First-time generic

- On May 23, 2022, Alkem launched an [AA-rated](#) generic version of UCB's [Vimpat \(lacosamide\)](#) oral solution.
- Vimpat is approved for the treatment of partial-onset seizures in patients 1 month of age and older, and as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
- Lacosamide is also available as a generic [oral capsule](#) and generic [intravenous solution](#).